Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data

Eur Neuropsychopharmacol. 2024 Apr:81:1-9. doi: 10.1016/j.euroneuro.2024.01.002. Epub 2024 Feb 3.

Abstract

The treatment of bipolar depression is one of the most challenging needs in contemporary psychiatry. Currently, only quetiapine, olanzapine-fluoxetine combination, lurasidone, cariprazine, and recently lumateperone have been FDA-approved to treat this condition. The neurobiology of bipolar depression and the possible mechanistic targets of bipolar antidepressant therapy remain elusive. The current study investigated whether the pharmacodynamic properties of lumateperone fit into a previously developed model which was the first to be derived based on the strict combination of clinical and preclinical data. The authors performed a systematic review of the literature to identify the pharmacodynamic properties of lumateperone. The original model suggests that a constellation of effects on different receptors is necessary, but refinements, including the present study, suggest that the inhibition of the serotonin reuptake at the first level, the 5HT-2A blockade at the second level, and the norepinephrine alpha-1 receptors blockade at a third level in combination with D1 blockade contribute to the antidepressant effect in acute bipolar depression. The D2 blockade acts as a protective mechanism and reduces the risk of switching to mania/hypomania.

Keywords: Biological models; Bipolar depression; Lumateperone; Neurobiology.

Publication types

  • Review

MeSH terms

  • Antidepressive Agents / pharmacology
  • Antidepressive Agents / therapeutic use
  • Antipsychotic Agents* / pharmacology
  • Antipsychotic Agents* / therapeutic use
  • Bipolar Disorder* / drug therapy
  • Heterocyclic Compounds, 4 or More Rings*
  • Humans
  • Lurasidone Hydrochloride / pharmacology
  • Lurasidone Hydrochloride / therapeutic use

Substances

  • lumateperone
  • Antipsychotic Agents
  • Lurasidone Hydrochloride
  • Antidepressive Agents
  • Heterocyclic Compounds, 4 or More Rings